Merck & Co. may look to repurpose some US facilities to support production of potential COVID-19 therapy MK-7110.

Millie Nelson, Editor

January 13, 2021

2 Min Read
Merck to scale-up acquired COVID candidate to meet OWS goal
Image: iStock/Sundry Photography

Merck & Co. may look to repurpose some US facilities to support production of potential COVID-19 therapy MK-7110.

In December 2020, the US Department of Health and Human Services (HHS) struck a $356 million deal with Merck & Co (known as MSD outside North America) to support production of MK-7110, a recombinant protein in Phase III trials as a therapy to treat hospitalized patients with acute COVID-19.

When announced, HHS said the Operation Warp Speed (OWS) collaboration was the latest example of company and government moving “potential therapeutics all the way from development through to manufacturing, enabling faster distribution,” and hoped for delivery of “up to 100,000 doses of MK-7110 by June 30, 2021.”

iStock-1210931291-300x200.jpg

Image: iStock/Sundry Photography

Merck said it is investing to meet the capacity needs for MK-7110 but details as to how it will do this were not revealed. However, on January 6 Homeland Preparedness News reported that Merck is going to repurpose four of its US facilities.

The article has since been taken down and Merck spokesman Patrick Ryan confirmed to Bioprocess Insider that repurposing plans are yet to be decided.

“We have not signed a deal. We continue to engage with the US government and other governments around the world regarding our vaccine and therapeutic programs,” said Ryan.

According to its 2019 annual report, Merck has manufacturing operations at its Whitehouse Station, New Jersey site, along with nine locations in the United States and Puerto Rico.

“With respect to MK-7110, Merck acquired OncoImmune to bring our resources and capabilities to help scale up manufacturing and make this potentially important medicine available as rapidly as possible.”

Merck added MK-7110 – previously known as CD24Fc – through the $425 million acquisition in November 2020 as part of their response to COVID-19.

With the unprecedented demand for COVID-19 vaccines and therapies, companies have opted to repurpose facilities to excel production. For example, Regeneron moved products out of its Renselaar, New York facility to Ireland to make way for COVID-19 mAbs.

Neil Stahl, executive vice president of Regeneron told investors in September: “We’re actually actively moving some of our products that are manufactured here in Rensselaer at our manufacturing facility […] so that we can have even more capacity here.”

About the Author(s)

Millie Nelson

Editor, BioProcess Insider

Journalist covering global biopharmaceutical manufacturing and processing news and host of the Voices of Biotech podcast.

I am currently living and working in London but I grew up in Lincolnshire (UK) and studied in Newcastle (UK).

Got a story? Feel free to email me at [email protected]

You May Also Like